BMS to Seek Approval for Nivolumab in the US to Treat Advanced Melanoma

Following approval in Japan, Nivolumab will be evaluated by the FDA for melanoma therapy in the US.
Published Online: July 10, 2014

Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected.

The company said it would seek approval to market the drug to patients who had previously been treated with Bristol-Myers' already approved melanoma drug Yervoy, which works through a different mechanism than Opdivo.

Mark Schoenebaum, an analyst with ISI Group, said many analysts had not expected Bristol-Myers to submit the marketing application until mid-2015, although he and some others had speculated an earlier filing was possible.

Opdivo was approved in Japan just this week to treat advanced melanoma, under license to Ono Pharmaceuticals.

Source: PubMed

 



Feature
Recommended Articles
A research team at the Barts Cancer Institute in London has identified a 3-protein molecular signature in pancreatic cancer patients.
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
The discovery could lead to targeted therapy in triple negative breast cancer patients.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.